Wedmont Private Capital Invests $725,000 in United Therapeutics Corporation $UTHR

Wedmont Private Capital purchased a new position in United Therapeutics Corporation (NASDAQ:UTHR) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 1,587 shares of the biotechnology company’s stock, valued at approximately $725,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of UTHR. Chung Wu Investment Group LLC bought a new position in United Therapeutics during the 2nd quarter worth approximately $29,000. SVB Wealth LLC acquired a new stake in shares of United Therapeutics during the 1st quarter valued at approximately $32,000. WealthCollab LLC lifted its stake in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares during the last quarter. Rakuten Securities Inc. lifted its stake in United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares during the last quarter. Finally, Geneos Wealth Management Inc. boosted its holdings in United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 85 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In other United Therapeutics news, CEO Martine A. Rothblatt sold 2,000 shares of United Therapeutics stock in a transaction on Friday, December 19th. The stock was sold at an average price of $507.07, for a total transaction of $1,014,140.00. Following the sale, the chief executive officer owned 130 shares of the company’s stock, valued at $65,919.10. The trade was a 93.90% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Christopher Patusky sold 1,000 shares of the stock in a transaction on Monday, December 15th. The stock was sold at an average price of $495.95, for a total value of $495,950.00. Following the completion of the transaction, the director directly owned 1,490 shares of the company’s stock, valued at approximately $738,965.50. The trade was a 40.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 625,164 shares of company stock worth $284,916,107 over the last quarter. Insiders own 10.30% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. HC Wainwright increased their target price on shares of United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Jefferies Financial Group reaffirmed a “buy” rating and set a $575.00 price objective on shares of United Therapeutics in a research report on Wednesday, November 19th. Oppenheimer raised their target price on shares of United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a report on Friday, September 5th. Cantor Fitzgerald lifted their target price on United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a research note on Wednesday, September 10th. Finally, UBS Group upped their target price on United Therapeutics from $580.00 to $600.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and an average target price of $505.00.

Key United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Director Tommy G. Thompson sold 910 shares but still holds 8,480 shares (~$4.25M), signaling continued insider alignment with shareholders. SEC Filing — Thompson Sale
• Neutral Sentiment: All transactions were disclosed via SEC filings and covered by financial sites, providing transparency; investors should check the filings for whether sales were part of pre-set programs (e.g., 10b5-1) that reduce interpretive weight. SEC Filings
• Negative Sentiment: CEO Martine A. Rothblatt sold a total of 6,000 shares across Dec. 17 and Dec. 19 at ~ $501–$507, leaving her with only 130 shares — a ~94%+ reduction in reported ownership; that sharp drop can be read as a meaningful negative signal to some investors. SEC Filing — Rothblatt Sales
• Negative Sentiment: Additional senior insider sales: CFO and COO transactions reported (CFO ~$1.74M; COO ~$11.17M), increasing the volume and scope of executive selling within days — a likely near-term headwind for sentiment absent an explanatory disclosure. ABN: CEO Sale Coverage ABN: CFO Sale Coverage ABN: COO Sale Coverage

United Therapeutics Stock Up 2.0%

United Therapeutics stock opened at $517.13 on Friday. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $518.61. The firm has a market capitalization of $22.27 billion, a price-to-earnings ratio of 19.60, a PEG ratio of 5.03 and a beta of 0.86. The firm has a 50-day moving average price of $463.63 and a two-hundred day moving average price of $380.56.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, beating the consensus estimate of $6.89 by $0.27. The company had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. United Therapeutics’s revenue was up 6.8% compared to the same quarter last year. During the same quarter last year, the business earned $6.39 earnings per share. Research analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.